S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
NASDAQ:ACIU

AC Immune Stock Forecast, Price & News

$4.34
-0.12 (-2.69%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.30
$4.50
50-Day Range
$4.34
$5.78
52-Week Range
$4.30
$12.61
Volume
167,175 shs
Average Volume
125,698 shs
Market Capitalization
$315.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.82
30 days | 90 days | 365 days | Advanced Chart
Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.


AC Immune logo

About AC Immune

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Headlines

AC Immune Gains First Things Monday
November 8, 2021 |  baystreet.ca
AC Immune Gains First Thing Monday
November 8, 2021 |  baystreet.ca
AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates
November 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACIU
Employees
137
Year Founded
N/A

Sales & Book Value

Annual Sales
$16.46 million
Book Value
$3.20 per share

Profitability

Net Income
$-66.04 million
Pretax Margin
-7,453.11%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$315.31 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/08/2021
Today
1/21/2022
Next Earnings (Estimated)
3/22/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

982nd out of 1,418 stocks

Pharmaceutical Preparations Industry

479th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












AC Immune (NASDAQ:ACIU) Frequently Asked Questions

Is AC Immune a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AC Immune stock.
View analyst ratings for AC Immune
or view top-rated stocks.

How has AC Immune's stock been impacted by Coronavirus (COVID-19)?

AC Immune's stock was trading at $5.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACIU shares have decreased by 20.9% and is now trading at $4.34.
View which stocks have been most impacted by COVID-19
.

When is AC Immune's next earnings date?

AC Immune is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for AC Immune
.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03.
View AC Immune's earnings history
.

What price target have analysts set for ACIU?

2 brokers have issued 12-month price targets for AC Immune's stock. Their forecasts range from $15.00 to $16.00. On average, they expect AC Immune's share price to reach $15.50 in the next year. This suggests a possible upside of 257.1% from the stock's current price.
View analysts' price targets for AC Immune
or view top-rated stocks among Wall Street analysts.

Who are AC Immune's key executives?

AC Immune's management team includes the following people:
  • Andrea Pfeifer, Chief Executive Officer & Director
  • Jörg Hornstein, Chief Financial Officer
  • Piergiorgio Donati, Chief Technical Operations Officer
  • Marie Kosco-Vilbois, Chief Scientific Officer
  • Johannes Rolf Streffer, Chief Medical Officer

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune CEO Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among AC Immune's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?

When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Who are AC Immune's major shareholders?

AC Immune's stock is owned by many different retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%).

Which major investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $4.34.

How much money does AC Immune make?

AC Immune has a market capitalization of $315.31 million and generates $16.46 million in revenue each year. The company earns $-66.04 million in net income (profit) each year or ($1.08) on an earnings per share basis.

How many employees does AC Immune have?

AC Immune employs 137 workers across the globe.

What is AC Immune's official website?

The official website for AC Immune is www.acimmune.com.

Where are AC Immune's headquarters?

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at (121) 693-9121, via email at [email protected], or via fax at 41-21-345-9120.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.